• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种建模方法,用于探究缺血性中风患者神经保护试验失败的一些假说。

A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients.

作者信息

Dronne Marie-Aimée, Grenier Emmanuel, Chapuisat Guillemette, Hommel Marc, Boissel Jean-Pierre

机构信息

Université de Lyon, Lyon, F-69003, France.

出版信息

Prog Biophys Mol Biol. 2008 May;97(1):60-78. doi: 10.1016/j.pbiomolbio.2007.10.001. Epub 2007 Oct 30.

DOI:10.1016/j.pbiomolbio.2007.10.001
PMID:18076975
Abstract

Ischemic stroke is the third cause of death in industrialised countries, but no satisfactory treatment is currently available. The hundreds of neuroprotective drugs developed to block the ischemic cascade gave very promising results in animal models but the clinical trials performed with these drugs showed no beneficial effects in stroke patients. Many hypotheses were advanced to explain this discrepancy, among which the morphological and functional differences between human and rodent brains. This discrepancy could be partly due to the differences in white matter and glial cell proportions between human and rodent brains. In order to test this hypothesis, we built a mathematical model of the main early pathophysiological mechanisms of stroke in rodent and in human brains. This model is a two-scale model and relies on a set of ordinary differential equations. We built two versions of this model (for human and rodent brains) differing in their white matter and glial cell proportions. Then, we carried out in silico experiments with various neuroprotective drugs. The simulation results obtained with a sodium channel blocker show that the proportion of penumbra recovery is much higher in rodent than in human brain and the results are similar with some other neuroprotective drugs tested during phase III trials. This in silico investigation suggests that the proportions of glial cells and white matter have an influence on neuroprotective drug efficacy. It reinforces the hypothesis that histological and morphological differences between rodent and human brains can partly explain the failure of these agents in clinical trials.

摘要

缺血性中风是工业化国家的第三大死因,但目前尚无令人满意的治疗方法。为阻断缺血级联反应而研发的数百种神经保护药物在动物模型中取得了非常有前景的结果,但用这些药物进行的临床试验在中风患者中并未显示出有益效果。人们提出了许多假说来解释这种差异,其中包括人类和啮齿动物大脑在形态和功能上的差异。这种差异可能部分归因于人类和啮齿动物大脑在白质和胶质细胞比例上的差异。为了验证这一假说,我们构建了一个关于啮齿动物和人类大脑中风主要早期病理生理机制的数学模型。该模型是一个双尺度模型,依赖于一组常微分方程。我们构建了该模型的两个版本(针对人类和啮齿动物大脑),它们在白质和胶质细胞比例上有所不同。然后,我们用各种神经保护药物进行了计算机模拟实验。用钠通道阻滞剂获得的模拟结果表明,啮齿动物大脑中半暗带恢复的比例远高于人类大脑,并且与在III期试验中测试的其他一些神经保护药物的结果相似。这项计算机模拟研究表明,胶质细胞和白质的比例会影响神经保护药物的疗效。它强化了这样一种假说,即啮齿动物和人类大脑之间的组织学和形态学差异可以部分解释这些药物在临床试验中的失败。

相似文献

1
A modelling approach to explore some hypotheses of the failure of neuroprotective trials in ischemic stroke patients.一种建模方法,用于探究缺血性中风患者神经保护试验失败的一些假说。
Prog Biophys Mol Biol. 2008 May;97(1):60-78. doi: 10.1016/j.pbiomolbio.2007.10.001. Epub 2007 Oct 30.
2
Physiologically based model of acute ischemic stroke.急性缺血性中风的基于生理学的模型。
J Cereb Blood Flow Metab. 2002 Aug;22(8):1010-8. doi: 10.1097/00004647-200208000-00013.
3
In silico study of the influence of intensity and duration of blood flow reduction on cell death through necrosis or apoptosis during acute ischemic stroke.急性缺血性卒中期间,血流减少的强度和持续时间对通过坏死或凋亡导致的细胞死亡影响的计算机模拟研究。
Acta Biotheor. 2010 Sep;58(2-3):171-90. doi: 10.1007/s10441-010-9100-2. Epub 2010 Jul 28.
4
[Neuroprotection in brain ischemia--doubts and hopes].[脑缺血中的神经保护——疑虑与希望]
Ideggyogy Sz. 2004 Mar 20;57(3-4):81-93.
5
Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia.急性缺血性卒中:主要实验性啮齿动物模型、病理生理学及局灶性脑缺血治疗概述
Pharmacol Biochem Behav. 2007 May;87(1):179-97. doi: 10.1016/j.pbb.2007.04.015. Epub 2007 May 4.
6
Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics.缺血性中风中的损伤与修复机制:新型神经治疗药物研发的考量因素
Curr Opin Investig Drugs. 2009 Jul;10(7):644-54.
7
A global phenomenological model of ischemic stroke with stress on spreading depressions.一种强调扩散性抑制的缺血性中风的全球现象学模型。
Prog Biophys Mol Biol. 2008 May;97(1):4-27. doi: 10.1016/j.pbiomolbio.2007.10.004. Epub 2007 Nov 1.
8
Recanalization and reperfusion therapies for acute ischemic stroke.急性缺血性脑卒中的再通和再灌注治疗
Cerebrovasc Dis. 2009;27 Suppl 1:162-7. doi: 10.1159/000200455. Epub 2009 Apr 3.
9
[Neuroprotective agents].[神经保护剂]
Neurologia. 1999;14 Suppl 4:49-53.
10
SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.SB 234551选择性内皮素A(ET(A))受体拮抗作用:灌注/扩散磁共振成像用于定义可治疗性中风模型、治疗时间及保护机制。
Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

引用本文的文献

1
Systems-level computational modeling in ischemic stroke: from cells to patients.缺血性中风的系统级计算建模:从细胞到患者
Front Physiol. 2024 Jul 2;15:1394740. doi: 10.3389/fphys.2024.1394740. eCollection 2024.
2
Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma.考虑不确定性和变异性的时间事件数学模型验证的经验方法:在 EGFR+肺腺癌中的应用。
BMC Bioinformatics. 2023 Sep 4;24(1):331. doi: 10.1186/s12859-023-05430-w.
3
Predictive validity in drug discovery: what it is, why it matters and how to improve it.
药物发现中的预测有效性:是什么,为什么重要以及如何提高它。
Nat Rev Drug Discov. 2022 Dec;21(12):915-931. doi: 10.1038/s41573-022-00552-x. Epub 2022 Oct 4.
4
Neuroprotective Treatment of Postanoxic Encephalopathy: A Review of Clinical Evidence.缺氧后脑病的神经保护治疗:临床证据综述
Front Neurol. 2021 Feb 18;12:614698. doi: 10.3389/fneur.2021.614698. eCollection 2021.
5
Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms.联合治疗:多靶点调控二次脑损伤机制
Curr Neuropharmacol. 2018;16(4):484-504. doi: 10.2174/1570159X15666170828165711.
6
Bridging Systems Medicine and Patient Needs.衔接系统医学与患者需求。
CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00026. doi: 10.1002/psp4.26. Epub 2015 Mar 27.
7
Effect model law: an approach for the implementation of personalized medicine.效应模型定律:实施个性化医疗的一种方法。
J Pers Med. 2013 Aug 15;3(3):177-90. doi: 10.3390/jpm3030177.
8
Oligodendrocyte pathophysiology and treatment strategies in cerebral ischemia.脑缺血中少突胶质细胞的病理生理学及治疗策略
CNS Neurosci Ther. 2014 Jul;20(7):603-12. doi: 10.1111/cns.12263. Epub 2014 Apr 7.
9
Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions.缺血性中风的神经保护:克服缺点并确定有前景的方向。
Int J Mol Sci. 2013 Jan 17;14(1):1890-917. doi: 10.3390/ijms14011890.
10
Age and the metabolic syndrome as risk factors for ischemic stroke: improving preclinical models of ischemic stroke.年龄和代谢综合征作为缺血性脑卒中的危险因素:改善缺血性脑卒中的临床前模型。
Yale J Biol Med. 2012 Dec;85(4):523-39. Epub 2012 Dec 13.